These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27490795)

  • 1. Six-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPF.
    Ashley SL; Xia M; Murray S; O'Dwyer DN; Grant E; White ES; Flaherty KR; Martinez FJ; Moore BB
    PLoS One; 2016; 11(8):e0159878. PubMed ID: 27490795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry.
    Todd JL; Neely ML; Overton R; Durham K; Gulati M; Huang H; Roman J; Newby LK; Flaherty KR; Vinisko R; Liu Y; Roy J; Schmid R; Strobel B; Hesslinger C; Leonard TB; Noth I; Belperio JA; Palmer SM;
    Respir Res; 2019 Oct; 20(1):227. PubMed ID: 31640794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normal Lung Quantification in Usual Interstitial Pneumonia Pattern: The Impact of Threshold-based Volumetric CT Analysis for the Staging of Idiopathic Pulmonary Fibrosis.
    Ohkubo H; Kanemitsu Y; Uemura T; Takakuwa O; Takemura M; Maeno K; Ito Y; Oguri T; Kazawa N; Mikami R; Niimi A
    PLoS One; 2016; 11(3):e0152505. PubMed ID: 27031615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [
    Justet A; Laurent-Bellue A; Thabut G; Dieudonné A; Debray MP; Borie R; Aubier M; Lebtahi R; Crestani B
    Respir Res; 2017 Apr; 18(1):74. PubMed ID: 28449678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias.
    White ES; Xia M; Murray S; Dyal R; Flaherty CM; Flaherty KR; Moore BB; Cheng L; Doyle TJ; Villalba J; Dellaripa PF; Rosas IO; Kurtis JD; Martinez FJ
    Am J Respir Crit Care Med; 2016 Nov; 194(10):1242-1251. PubMed ID: 27149370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.
    Xue M; Guo Z; Cai C; Sun B; Wang H
    Respiration; 2019; 98(6):534-545. PubMed ID: 31665737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis.
    Tzouvelekis A; Herazo-Maya JD; Slade M; Chu JH; Deiuliis G; Ryu C; Li Q; Sakamoto K; Ibarra G; Pan H; Gulati M; Antin-Ozerkis D; Herzog EL; Kaminski N
    Respirology; 2017 Apr; 22(3):486-493. PubMed ID: 27761978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis.
    Sokai A; Handa T; Tanizawa K; Oga T; Uno K; Tsuruyama T; Kubo T; Ikezoe K; Nakatsuka Y; Tanimura K; Muro S; Hirai T; Nagai S; Chin K; Mishima M
    Respir Res; 2015 Sep; 16():120. PubMed ID: 26415518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis.
    Ando M; Miyazaki E; Ito T; Hiroshige S; Nureki SI; Ueno T; Takenaka R; Fukami T; Kumamoto T
    Lung; 2010 Jun; 188(3):247-52. PubMed ID: 20066538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma microRNAs are associated with acute exacerbation in idiopathic pulmonary fibrosis.
    Min H; Fan S; Song S; Zhuang Y; Li H; Wu Y; Cai H; Yi L; Dai J; Gao Q
    Diagn Pathol; 2016 Nov; 11(1):135. PubMed ID: 27881157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Impact of Emphysema Evaluated by High-Resolution Computed Tomography on Idiopathic Pulmonary Fibrosis Diagnosed by Surgical Lung Biopsy.
    Kohashi Y; Arai T; Sugimoto C; Tachibana K; Akira M; Kitaichi M; Hayashi S; Inoue Y
    Respiration; 2016; 92(4):220-228. PubMed ID: 27576553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis in non-small cell lung cancer: impact on survival and acute exacerbation.
    Moon SW; Park MS; Kim YS; Jang J; Lee JH; Lee CT; Chung JH; Shim HS; Lee KW; Kim SS; Lee SH; Yoon HI
    BMC Pulm Med; 2019 Oct; 19(1):177. PubMed ID: 31615505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical value of angiogenin in predicting the prognosis of patients with idiopathic pulmonary fibrosis].
    Bai Y; Zhu H; Sun Q; Gu G; Zhang L; Li Y; Yang B
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 Sep; 29(9):789-793. PubMed ID: 28936953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
    Ikeda K; Shiratori M; Chiba H; Nishikiori H; Yokoo K; Saito A; Hasegawa Y; Kuronuma K; Otsuka M; Yamada G; Takahashi H
    Respir Med; 2017 Oct; 131():184-191. PubMed ID: 28947028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant populations of circulating T follicular helper cells and regulatory B cells underlying idiopathic pulmonary fibrosis.
    Asai Y; Chiba H; Nishikiori H; Kamekura R; Yabe H; Kondo S; Miyajima S; Shigehara K; Ichimiya S; Takahashi H
    Respir Res; 2019 Nov; 20(1):244. PubMed ID: 31694639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic Biomarkers of Survival in Idiopathic Pulmonary Fibrosis.
    Oldham JM; Huang Y; Bose S; Ma SF; Kim JS; Schwab A; Ting C; Mou K; Lee CT; Adegunsoye A; Ghodrati S; Pugashetti JV; Nazemi N; Strek ME; Linderholm AL; Chen CH; Murray S; Zemans RL; Flaherty KR; Martinez FJ; Noth I
    Am J Respir Crit Care Med; 2024 May; 209(9):1111-1120. PubMed ID: 37847691
    [No Abstract]   [Full Text] [Related]  

  • 17. Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers.
    Raghu G; Richeldi L; Jagerschmidt A; Martin V; Subramaniam A; Ozoux ML; Esperet CA; Soubrane C
    Chest; 2018 Dec; 154(6):1359-1370. PubMed ID: 30526970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.
    Zappala CJ; Latsi PI; Nicholson AG; Colby TV; Cramer D; Renzoni EA; Hansell DM; du Bois RM; Wells AU
    Eur Respir J; 2010 Apr; 35(4):830-6. PubMed ID: 19840957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Label-free plasma proteomics identifies haptoglobin-related protein as candidate marker of idiopathic pulmonary fibrosis and dysregulation of complement and oxidative pathways.
    Saraswat M; Joenväärä S; Tohmola T; Sutinen E; Vartiainen V; Koli K; Myllärniemi M; Renkonen R
    Sci Rep; 2020 May; 10(1):7787. PubMed ID: 32385381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of IFN-γ, sCD163, CCL2 and CXCL10 involved in acute exacerbation of idiopathic pulmonary fibrosis.
    Gui X; Qiu X; Tian Y; Xie M; Li H; Gao Y; Zhuang Y; Cao M; Ding H; Ding J; Zhang Y; Cai H
    Int Immunopharmacol; 2019 May; 70():208-215. PubMed ID: 30851700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.